Right. I have no doubt this is the plan.... The infusion division I believe is profitable to the tune of around $2 million a year and is growing revenues and profits at a decent click....
But, where would you prefer to be allocating capital?
To the infusion division which is growing modestly and has good but not great gross profit margins? Or to the regenerative division which is set to explode revenue growth (growth predicted at 160%) this year, has excellent gross profit margins (I predict in the region of 75-80%) when the 3D portfolio really gets going (currently I believe at 67-70%), has a pipeline project of 16 new products, has a revolutionary TAVR device, has significant competitive advantages over competitor's products and has a significant 'moat' against current and competitor's products.... I know where I'd be allocating the capital and I think we'll see Wayne do the same in the coming years.
Time will tell.
Right. I have no doubt this is the plan.... The infusion...
-
- There are more pages in this discussion • 143 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.000(0.00%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.33 | $13.91 | $13.14 | $302.2K | 22.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 299 | $13.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.49 | 35 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |